CN1166365C - 阿仑膦酸的药物组合物及其在制备抑制人的骨吸收的药物中的用途 - Google Patents
阿仑膦酸的药物组合物及其在制备抑制人的骨吸收的药物中的用途 Download PDFInfo
- Publication number
- CN1166365C CN1166365C CNB988074737A CN98807473A CN1166365C CN 1166365 C CN1166365 C CN 1166365C CN B988074737 A CNB988074737 A CN B988074737A CN 98807473 A CN98807473 A CN 98807473A CN 1166365 C CN1166365 C CN 1166365C
- Authority
- CN
- China
- Prior art keywords
- phosphonic acids
- bis
- bone
- alendronic acid
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
食管刺激可能性研究 | ||||
组别 | 活性剂mg/ml | 用药方案 | 宰杀时间 | 病理组织学 |
1(n=4) | 0 | 每日1次共5日 | 紧接着最后一次用药之后 | 正常。完好的上皮,粘膜下层无炎性细胞。 |
2(n=4) | 阿仑膦酸类0.20 | 每日1次共5日 | 紧接着最后一次用药之后 | 上皮表面深度溃疡。显著粘膜下层发炎和空泡形成。 |
3(n=5) | 阿仑膦酸类0.80 | 1次 | 用药后24小时 | 完好的上皮表面,轻微的粘膜下层发炎和空泡形成。 |
4(n=5) | 阿仑膦酸类0.80 | 1次 | 用药后7日 | 完好的上皮,或者很少发炎(2/5的动物)或者没有发炎(3/5的动物)并且无空泡形成。 |
5(n=6) | 阿仑膦酸类0.80 | 每周1次共4次 | 用药后7日 | 完好的上皮,没有发炎,无空泡形成。 |
6(n=6) | 阿仑膦酸类0.40 | 每周2次共4周 | 紧接着最后一次用药之后 | 上皮表面深度溃疡。显著粘膜下层发炎和空泡形成。 |
7(n=8) | 瑞日膦酸类0.20 | 每日1次共5日 | 紧接着最后一次用药之后 | 上皮表面深度溃疡(4/8的动物)。显著粘膜下层发炎和空泡形成。 |
8(n=4) | 替鲁膦酸类4.0 | 每日1次共5日 | 最后一次用药24小时 | 轻微的粘膜下层发炎和空泡形成(3/4的动物,这些动物之一有轻微的溃疡) |
Claims (14)
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5335197P | 1997-07-22 | 1997-07-22 | |
US60/053351 | 1997-07-22 | ||
US60/053,351 | 1997-07-22 | ||
US5353597P | 1997-07-23 | 1997-07-23 | |
US60/053,535 | 1997-07-23 | ||
US60/053535 | 1997-07-23 | ||
GB9717590.5 | 1997-08-20 | ||
GBGB9717590.5A GB9717590D0 (en) | 1997-08-20 | 1997-08-20 | Oral method for treating or preventing abnormal bone resorption |
US9717590.5 | 1997-08-20 | ||
GBGB9717850.3A GB9717850D0 (en) | 1997-08-22 | 1997-08-22 | Oral method for treating or preventing abnormal bone resorption |
GB9717850.3 | 1997-08-22 | ||
US9717850.3 | 1997-08-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004100557346A Division CN1602879A (zh) | 1997-07-22 | 1998-07-17 | 抑制骨吸收的方法 |
CNB2004100557350A Division CN1299689C (zh) | 1997-07-22 | 1998-07-17 | 阿仑膦酸在制备抑制骨吸收药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1265035A CN1265035A (zh) | 2000-08-30 |
CN1166365C true CN1166365C (zh) | 2004-09-15 |
Family
ID=27451690
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100557350A Expired - Lifetime CN1299689C (zh) | 1997-07-22 | 1998-07-17 | 阿仑膦酸在制备抑制骨吸收药物中的用途 |
CNB988074737A Ceased CN1166365C (zh) | 1997-07-22 | 1998-07-17 | 阿仑膦酸的药物组合物及其在制备抑制人的骨吸收的药物中的用途 |
CNA2004100557346A Pending CN1602879A (zh) | 1997-07-22 | 1998-07-17 | 抑制骨吸收的方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100557350A Expired - Lifetime CN1299689C (zh) | 1997-07-22 | 1998-07-17 | 阿仑膦酸在制备抑制骨吸收药物中的用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004100557346A Pending CN1602879A (zh) | 1997-07-22 | 1998-07-17 | 抑制骨吸收的方法 |
Country Status (31)
Country | Link |
---|---|
EP (5) | EP1175904B8 (zh) |
JP (2) | JP3479780B2 (zh) |
KR (3) | KR100391732B1 (zh) |
CN (3) | CN1299689C (zh) |
AT (2) | ATE209037T1 (zh) |
AU (1) | AU8493698A (zh) |
BG (1) | BG66282B1 (zh) |
BR (1) | BR9810779A (zh) |
CA (1) | CA2294595C (zh) |
CY (2) | CY1107535T1 (zh) |
DE (6) | DE69803291T2 (zh) |
DK (2) | DK1175904T3 (zh) |
EA (1) | EA004544B2 (zh) |
EE (1) | EE05603B1 (zh) |
ES (3) | ES2164447T3 (zh) |
HK (5) | HK1024166A1 (zh) |
ID (1) | ID24096A (zh) |
IL (1) | IL133535A0 (zh) |
IS (3) | IS5315A (zh) |
LU (2) | LU91222I2 (zh) |
NL (2) | NL300223I1 (zh) |
NO (1) | NO20000323L (zh) |
NZ (1) | NZ501807A (zh) |
PL (1) | PL195272B1 (zh) |
PT (2) | PT998292E (zh) |
SG (2) | SG109478A1 (zh) |
SI (1) | SI0998292T1 (zh) |
SK (1) | SK932000A3 (zh) |
TR (1) | TR200000145T2 (zh) |
UY (1) | UY25950A1 (zh) |
WO (1) | WO1999004773A2 (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1151793C (zh) | 1998-12-25 | 2004-06-02 | 山之内制药株式会社 | 多发性骨髓瘤的骨病变治疗用医药组合物 |
ES2240106T3 (es) * | 1999-05-21 | 2005-10-16 | Novartis Ag | Uso de acidos bisfosfonicos para el tratamiento de angiogenesis. |
DE60043648D1 (de) * | 1999-07-19 | 2010-02-25 | Toray Industries | Medikamente zur behandlung von periodontalen erkrankungen |
WO2001046040A1 (en) | 1999-12-20 | 2001-06-28 | Merck & Co., Inc. | Blister package for pharmaceutical treatment card |
US20010044427A1 (en) * | 1999-12-20 | 2001-11-22 | Sidney Mazel | Pharmaceutical kit |
EP1267890A2 (en) * | 2000-04-07 | 2003-01-02 | The Board of Regents of The University of Texas System | Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity |
AU7410901A (en) | 2000-06-20 | 2002-01-02 | Novartis Ag | Method of administering bisphosphonates |
US6638920B2 (en) * | 2000-07-21 | 2003-10-28 | Merck & Co., Inc. | Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses |
SE0101379D0 (sv) * | 2001-04-18 | 2001-04-18 | Diabact Ab | Komposition som hämmar utsöndring av magsyra |
BR0209360A (pt) * | 2001-05-02 | 2004-06-08 | Novartis Ag | Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose |
KR100642961B1 (ko) * | 2002-05-10 | 2006-11-10 | 에프. 호프만-라 로슈 아게 | 골다공증 치료 및 예방용 비스포스폰산 |
SE0203065D0 (sv) * | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
CA2539359A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate |
WO2005072747A1 (ja) * | 2004-02-02 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | 骨吸収抑制剤 |
NZ567200A (en) * | 2005-09-16 | 2010-08-27 | Selamine Ltd | Bisphosphonate formulation |
CA2820019A1 (en) * | 2010-12-06 | 2012-06-14 | Effrx Pharmaceuticals Sa | Stable effervescent bisphosphonate formulations with rapid solubilization characteristics |
CN106924257B (zh) * | 2017-03-14 | 2019-11-19 | 湖南赛隆药业有限公司 | 质子泵抑制剂和抗骨质疏松药的复合物及其用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL84731A0 (en) * | 1986-12-19 | 1988-05-31 | Norwich Eaton Pharma | Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them |
SE8704436D0 (sv) * | 1987-11-13 | 1987-11-13 | Pm Konsult Handelsbolag | Anvendning av antisekretoriska substanser for nya indikationer |
ATE122228T1 (de) * | 1991-07-01 | 1995-05-15 | Gergely Gerhard | Verfahren zur herstellung einer pharmazeutischen zubereitung mit wenigstens zwei verschiedenen wirkstoffen und verwendung einer solchen zubereitung. |
ES2149781T3 (es) * | 1991-11-22 | 2000-11-16 | Procter & Gamble Pharma | Composiciones de risedronato de liberacion retardada. |
US5270365A (en) * | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
US5294433A (en) * | 1992-04-15 | 1994-03-15 | The Procter & Gamble Company | Use of H-2 antagonists for treatment of gingivitis |
WO1994000129A1 (en) * | 1992-06-30 | 1994-01-06 | Procter & Gamble Pharmaceuticals, Inc. | Use of phosphonates for the treatment of osteoporosis |
US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
US5646134A (en) * | 1994-04-21 | 1997-07-08 | Merck & Co., Inc. | Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices |
AU703887B2 (en) * | 1995-06-06 | 1999-04-01 | Merck & Co., Inc. | Bisphosphonate therapy for bone loss associated with rheumatoid arthritis |
DE69726879T2 (de) * | 1996-05-17 | 2004-10-14 | Merck & Co., Inc. | Biphosphonat-formulierung mit brausewirkung |
-
1998
- 1998-07-17 AT AT98935752T patent/ATE209037T1/de active
- 1998-07-17 SI SI9830086T patent/SI0998292T1/xx unknown
- 1998-07-17 PT PT98935752T patent/PT998292E/pt unknown
- 1998-07-17 DE DE69803291T patent/DE69803291T2/de not_active Revoked
- 1998-07-17 CN CNB2004100557350A patent/CN1299689C/zh not_active Expired - Lifetime
- 1998-07-17 CN CNB988074737A patent/CN1166365C/zh not_active Ceased
- 1998-07-17 ES ES98935752T patent/ES2164447T3/es not_active Expired - Lifetime
- 1998-07-17 DE DE200712000063 patent/DE122007000063I1/de active Pending
- 1998-07-17 EE EEP200000040A patent/EE05603B1/xx unknown
- 1998-07-17 DE DE1998603291 patent/DE122006000009I1/de active Pending
- 1998-07-17 TR TR2000/00145T patent/TR200000145T2/xx unknown
- 1998-07-17 DE DE01201911T patent/DE01201911T1/de active Pending
- 1998-07-17 ES ES01201913T patent/ES2269014T3/es not_active Expired - Lifetime
- 1998-07-17 AU AU84936/98A patent/AU8493698A/en not_active Abandoned
- 1998-07-17 BR BR9810779-8A patent/BR9810779A/pt not_active Application Discontinuation
- 1998-07-17 EP EP01201913A patent/EP1175904B8/en not_active Revoked
- 1998-07-17 EP EP98935752A patent/EP0998292B1/en not_active Revoked
- 1998-07-17 CN CNA2004100557346A patent/CN1602879A/zh active Pending
- 1998-07-17 ID IDW20000114A patent/ID24096A/id unknown
- 1998-07-17 NZ NZ501807A patent/NZ501807A/en not_active IP Right Cessation
- 1998-07-17 SK SK93-2000A patent/SK932000A3/sk not_active Application Discontinuation
- 1998-07-17 DK DK01201913T patent/DK1175904T3/da active
- 1998-07-17 KR KR1020007000680A patent/KR100391732B1/ko not_active IP Right Cessation
- 1998-07-17 DK DK98935752T patent/DK0998292T3/da active
- 1998-07-17 SG SG200107221A patent/SG109478A1/en unknown
- 1998-07-17 EP EP01201910A patent/EP1132088A3/en not_active Ceased
- 1998-07-17 WO PCT/US1998/014796 patent/WO1999004773A2/en active Application Filing
- 1998-07-17 PT PT01201913T patent/PT1175904E/pt unknown
- 1998-07-17 DE DE01201913T patent/DE01201913T1/de active Pending
- 1998-07-17 ES ES01201910T patent/ES2253136T1/es active Pending
- 1998-07-17 DE DE69837450T patent/DE69837450T2/de not_active Expired - Lifetime
- 1998-07-17 KR KR1020027013595A patent/KR20030097611A/ko not_active Application Discontinuation
- 1998-07-17 AT AT01201913T patent/ATE357921T1/de active
- 1998-07-17 EP EP01201912A patent/EP1175903A3/en not_active Ceased
- 1998-07-17 EP EP01201911A patent/EP1151752A3/en not_active Ceased
- 1998-07-17 PL PL98338635A patent/PL195272B1/pl unknown
- 1998-07-17 CA CA002294595A patent/CA2294595C/en not_active Expired - Fee Related
- 1998-07-17 SG SG200603406-0A patent/SG139556A1/en unknown
- 1998-07-17 IL IL13353598A patent/IL133535A0/xx unknown
- 1998-07-17 JP JP50991499A patent/JP3479780B2/ja not_active Expired - Lifetime
- 1998-07-17 EA EA200000151A patent/EA004544B2/ru not_active IP Right Cessation
- 1998-07-17 KR KR1020027013594A patent/KR20030097610A/ko not_active Application Discontinuation
-
1999
- 1999-12-21 IS IS5315A patent/IS5315A/is unknown
-
2000
- 2000-01-17 UY UY25950A patent/UY25950A1/es not_active Application Discontinuation
- 2000-01-18 BG BG104093A patent/BG66282B1/bg unknown
- 2000-01-21 NO NO20000323A patent/NO20000323L/no unknown
- 2000-05-12 HK HK00102840A patent/HK1024166A1/xx not_active IP Right Cessation
-
2002
- 2002-03-04 HK HK02101656.1A patent/HK1042230A1/zh unknown
- 2002-03-12 HK HK02101869.4A patent/HK1042232A1/zh unknown
- 2002-03-16 HK HK02102043.1A patent/HK1040495A1/zh unknown
- 2002-03-16 HK HK02102042.2A patent/HK1040494A1/zh unknown
-
2003
- 2003-03-10 JP JP2003063378A patent/JP2005068010A/ja active Pending
-
2004
- 2004-04-21 IS IS7231A patent/IS7231A/is unknown
- 2004-04-21 IS IS7230A patent/IS7230A/is unknown
-
2006
- 2006-02-07 NL NL300223C patent/NL300223I1/nl unknown
- 2006-02-15 LU LU91222C patent/LU91222I2/fr unknown
-
2007
- 2007-03-29 CY CY20071100442T patent/CY1107535T1/el unknown
- 2007-09-12 LU LU91364C patent/LU91364I2/fr unknown
- 2007-09-13 NL NL300292C patent/NL300292I1/nl unknown
- 2007-09-20 CY CY2007022C patent/CY2007022I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1166365C (zh) | 阿仑膦酸的药物组合物及其在制备抑制人的骨吸收的药物中的用途 | |
CN1277545C (zh) | 二膦酸类化合物在制备用于治疗与前列腺癌有关的骨转移瘤的药物中的用途 | |
CN1227004C (zh) | 治疗充血性心力衰竭的部分脂肪酸氧化抑制剂 | |
CN1142783C (zh) | 用于治疗高危葡萄糖耐量降低的药剂 | |
CN1535152A (zh) | 二膦酸类化合物在治疗疼痛方面的应用 | |
CN1615124A (zh) | 配方 | |
CN1671391A (zh) | 用于缓解疼痛的新方法及组合物 | |
CN1250371A (zh) | 用于控制释放活性物质的药物组合物 | |
CN1878555A (zh) | 包含n-(3-甲氧基-5-甲基吡嗪-2-基)-2-(4-[1,3,4-噁二唑- 2-基]苯基)吡啶-3-磺酰胺与lhrh类似物和/或二膦酸盐的联合药物 | |
CN1251527A (zh) | 使用延迟和/或持续释放的维生素d制剂治疗前列腺疾病的方法 | |
CN1646137A (zh) | 治疗和预防甲状旁腺机能亢进的方法 | |
JP2005516928A (ja) | 骨異常のためのビスホスホネート液体製剤 | |
CN1464788A (zh) | 用于头痛、偏头痛、恶心和呕吐的药物组合物 | |
CN87105828A (zh) | 苏灵大或苏灵大钠和碱的速效组合物 | |
CN1536988A (zh) | 缓释转运系统 | |
CN1681515A (zh) | 包含双膦酸类化合物和hmg-coa还原酶抑制剂的组合疗法 | |
CN1931143A (zh) | 口服控制释放的曲美他嗪药物组合物 | |
CN1794982A (zh) | 化合物用于预防药物诱导的细胞毒性的用途 | |
CN1681516A (zh) | 预防或减少髋部骨折后继发性骨折的方法 | |
CN1411386A (zh) | 低骨矿质密度的治疗 | |
CN1711090A (zh) | 用于治疗慢性淋巴细胞白血病的氮芥类似物和甲磺酸依马替尼的组合 | |
CN1684681A (zh) | 比西发定制剂 | |
CN1968686A (zh) | 脒腙盐、组合物、制备方法和使用方法 | |
CN1919200A (zh) | 抑制骨吸收的方法 | |
CN1087935C (zh) | 药剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: MERCK & CO. INC. Free format text: FORMER NAME OR ADDRESS: MERCK + CO., INC. |
|
CP03 | Change of name, title or address |
Address after: New Jersey, USA Patentee after: Merk & Co. Inc. Address before: New Jersey, USA Patentee before: MERCK & Co.,Inc. |
|
C35 | Partial or whole invalidation of patent or utility model | ||
IW01 | Full invalidation of patent right |
Decision date of declaring invalidation: 20071102 Decision number of declaring invalidation: 10569 |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: New Jersey, USA Patentee after: Schering Corporation Address before: New Jersey, USA Patentee before: Merk & Co. Inc. |
|
C35 | Partial or whole invalidation of patent or utility model | ||
IW01 | Full invalidation of patent right |
Decision date of declaring invalidation: 20071102 Decision number of declaring invalidation: 10569 Granted publication date: 20040915 |